Cargando…

Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trial

OBJECTIVE: To determine if misoprostol is safe and efficacious in preventing postpartum haemorrhage (PPH) when administered by trained traditional birth attendants (TBA) at home deliveries. DESIGN: A randomised, double-blind, placebo-controlled trial. SETTING: Chitral, Khyber Pakhtunkhwa Province, P...

Descripción completa

Detalles Bibliográficos
Autores principales: Mobeen, N, Durocher, J, Zuberi, NF, Jahan, N, Blum, J, Wasim, S, Walraven, G, Hatcher, J
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041931/
https://www.ncbi.nlm.nih.gov/pubmed/21176086
http://dx.doi.org/10.1111/j.1471-0528.2010.02807.x
Descripción
Sumario:OBJECTIVE: To determine if misoprostol is safe and efficacious in preventing postpartum haemorrhage (PPH) when administered by trained traditional birth attendants (TBA) at home deliveries. DESIGN: A randomised, double-blind, placebo-controlled trial. SETTING: Chitral, Khyber Pakhtunkhwa Province, Pakistan. POPULATION: A total of 1119 women giving birth at home. METHODS: From June 2006 to June 2008, consenting women were randomised to receive 600 μg oral misoprostol (n = 534) or placebo (n = 585) after delivery to determine whether misoprostol reduced the incidence of PPH (≥500 ml). MAIN OUTCOME MEASURES: The primary outcomes were measured blood loss ≥500 ml after delivery and drop in haemoglobin >2 g/dl from before to after delivery. RESULTS: Oral misoprostol was associated with a significant reduction in the rate of PPH (≥500 ml) (16.5 versus 21.9%; relative risk 0.76, 95% CI 0.59–0.97). There were no measurable differences between study groups for drop in haemoglobin >2 g/dl (relative risk 0.79, 95% CI 0.62–1.02); but significantly fewer women receiving misoprostol had a drop in haemoglobin >3 g/dl, compared with placebo (5.1 versus 9.6%; relative risk 0.53, 95% CI 0.34–0.83). Shivering and chills were significantly more common with misoprostol. There were no maternal deaths among participants. CONCLUSIONS: Postpartum administration of 600 μg oral misoprostol by trained TBAs at home deliveries reduces the rate of PPH by 24%. Given its ease of use and low cost, misoprostol could reduce the burden of PPH in community settings where universal oxytocin prophylaxis is not feasible. Continual training and skill-building for TBAs, along with monitoring and evaluation of programme effectiveness, should accompany any widespread introduction of this drug. TRIAL REGISTRATION: http://clinicaltrials.gov/NCT00120237 Misoprostol for the Prevention of Postpartum Hemorrhage in Rural Pakistan.